Lenalidomide Fresenius Kabi

Lenalidomide, the active ingredient in Lenalidomide Fresenius Kabi, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, clinics and procurement teams worldwide, with reliable logistics and regulatory support.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

- Multiple Myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Mantle Cell Lymphoma: contributes to disease control when used in combination therapy.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may be mild to moderate. - Nausea: feeling of sickness often accompanied by vomiting. - Rash: skin redness or mild eruption. - Constipation: difficulty passing stools. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Lenalidomide, clinicians should consider several safety precautions to minimize risks.

- Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception for both male and female patients. - Thrombosis prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Renal impairment: adjust monitoring and dosing in patients with reduced kidney function. - Hepatic impairment: monitor liver function tests regularly. - Infections: monitor for signs of infection and manage promptly. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure (e.g., rifampin, carbamazepine). - Anticoagulants: increased risk of bleeding when combined with warfarin or direct oral anticoagulants. - Immunosuppressants: heightened risk of infection when used with high‑dose steroids or cyclosporine.

Moderate Interactions (Monitor Closely): - P‑glycoprotein substrates: may alter plasma levels (e.g., digoxin). - Vaccines: live attenuated vaccines may be less effective; avoid during therapy. - Hormonal contraceptives: reduced efficacy; consider additional barrier methods.